Latest News

Novozymes bags Organobalance

Enzyme fermentation at Novozymes' pilot plant, in Bagsværd, Denmark © Novozymes


Denmark’s Novozymes has acquired microbial research company Organobalance GmbH. The German company owns a large collection of microbial strains, some of which date back to the 1920s, and has strong capabilities in microbial screening and assay technology.

Germany-based Organobalance specializes in developing natural microbial solutions for customers and partners across a number of industries including food, feed, and animal health. Now, the company with a staff of 29  has been bought up by Danish industrial enzymes and microorganism expert Novozymes for an undisclosed amount.

“The experience of Organobalance’s founding scientists, and the company’s know-how, immediately strengthen Novozymes’ existing capabilities within microbial technologies,” says Sebastian Søderberg, Vice President for New Business Development, Incubation & Acquisitions at Novozymes. “Organobalance will advance our understanding to develop new, sustainable solutions across industries, and provide us with additional commercial opportunities.”

Organobalance co-founder Christine Lang will continue as General Manager. Lang commented: “By becoming part of Novozymes, we will have access to a global R&D network and an extensive infrastructure to bring products to market – a clear advantage for us and our customers."

Merck and 4SC collaborate in immunooncology

Under the agreement, 4SC AG will sponsor clinical testing of a combination of its oral class I histone deacetylase (HDAC) blocker domatinostat (HDAC...

Researchers identify viral inflammation switch

Their findings in mice models that were infected with the Influenza A virus may have also impact on further virally induced inflammations,researchers...

Researchers find new indication for cancer drug

Julie Gavard and colleagues at the University of Nantes identified a new druggable target against glioblastoma, the most common and lethal type of...

European circular bioeconomy fund near closing

Hauck & Aufhäuser Fund Services S.A. will act as the Alternative Investment Fund Manager. The ECFB will provide access to equity, debt or...

Merry Christmas and a Happy New Year

ImCheck Therapeutics SAS raises €48m

The €48m financing was co-led by Pfizer Ventures, the venture capital arm of Pfizer Inc., and Bpifrance, with the new investors Wellington Partners,...

Novadiscovery takes off with €5 Series A financing

French in silico clinical trial specialist Novadiscovery said it will use the €5m tranche of a €7m Series A funding round with Debiopharm Innovation...